… , particularly as compared with nirmatrelvir–ritonavir. In addition, the … nirmatrelvir–ritonavir
for oral treatment of symptomatic participants at high risk for progression to severe Covid-19 …

… the current literature on nirmatrelvir and ritonavir efficacy in treating SARS-CoV-2 … nirmatrelvir
therapy on progression of acute COVID to long COVID and also its effects on long COVID …

… of nirmatrelvir–ritonavir was … nirmatrelvir–ritonavir for treating COVID‐19 patients. A previous
meta‐analysis by Zheng et al.showed that nirmatrelvir–ritonavir was effective for COVID‐19 …

… but also know which drugs can be safely coadministered to prevent unnecessary denial
of nirmatrelvir/ritonavir treatment or inappropriate withholding of long-term comedications. …

… with ritonavir to delay its metabolism and allow nirmatrelvir to … due to COVID-19, molnupiravir
and nirmatrelvir/ritonavir … %, respectively, for the two treatments. Molnupiravir should not be …

… nirmatrelvir–ritonavir treatment for COVID-19. At present, the difference in efficacy and safety
between nirmatrelvir–ritonavir … of nirmatrelvir–ritonavir treatment for COVID-19 compared …

… To identify potential differences between the antiviral treatment groups, as well as the … of
nirmatrelvir/ritonavir vs molnupiravir (Table 5). Only the patients who received antiviral treatment …

… We identified 13 ongoing studies investigating nirmatrelvir/ritonavir for treatment of COVID‐19,
which may change the findings of the review or the certainty of evidence, and broaden the …

… of nirmatrelvir plus ritonavir leading to its first authorizations and approval for the treatment of
COVID-19. … Treatment with nirmatrelvir plus ritonavir should be initiated as soon as possible …

… decrease in the rate of severe COVID-19 (adjusted HR 0.54; … for the patients treated with
nirmatrelvir/ritonavir with respect to … of COVID-19 receiving molnupiravir or nirmatrelvir/ritonavir. …